Rabies is a zoonotic neurological disease with 100% lethality. Some of the rare human 28 patients who survived after multiple drug treatment have inherited severe sequelae. The 29 objective of this study was to investigate the action of the transfection of antibodies against 30 rabies in the central nervous system of mice as target therapy for rabies.
Introduction
Results 70 Probing the transfection to mouse brains with Bioporter agent complexed with an FITC-71 antibody control protein (Genlantis) after intracerebral inoculations in mice showed fluorescent 72 foci at 4 and 6-hours post-injection in brain slices obtained in a cryomicrotome (Fig 1) , 73 evidencing the efficacy of the protein transfection to mouse brains. However, the fluorescence 74 technique performed with microscopic slide tissue fragments showed absence of fluorescent 75 foci using equine anti-IgG conjugate for the mice inoculated with the F(ab')₂ anti-RABV 76 Bioporter complex at concentrations of 50 and 250 μg/mL and Bioporter, for post-inoculation 77 periods of 4 and 6 h (Unpublished data).
78
Mice which received anti-RABV F(ab')₂ in conjunction with Hepes 48 h,p.i., the mice 79 in the control group had onset of rabies symptoms at 5 days post injection. About 90% of the 80 mice showed symptoms of 2 to 3 days, followed by death, with only one mouse showing no 81 symptoms throughout the experiment, resulting in 90% mortality. Only one mouse presented 82 symptoms late, at 9 days p.i., consolidating survival of 10%. The clinical signs observed were 83 anorexia, piloerection, arching of the back, and limb paralysis before death.
84
On the other hand, the morbidity/mortality rate in the group treated with Bioporter plus 85 anti-RABV F(ab')₂ was as low as 30% with a minimum incubation period of seven days, 86 resulting in a significant difference (p<0.0198) when compared to the control group (Fig 2) .
87
Bioporter alone had no significant action on RABV, as morbidity/mortality rates of 50 88 and 80% were found for mice treated with only Bioporter or Hepes 20 mM pH 7.4 solution, 89 respectively, after 48 h of RABV inoculation (p=0.3498), indicating that the reduced 90 morbidity/mortality rate in mice treated with anti-RABV F(ab')₂ transfected with Bioporter was 91 due to a specific intracellular neuralization effect (Unpublished data).
92
All dead animals were positive for direct immunofluorescence for RABV, with no 93 difference in fluorescence intensity between groups. Thirty days after viral inoculation, all 94 5 surviving mice were euthanized and negative by direct immunofluorescence and PCR for 95 RABV.
96
In summary, these results show that the transfection of anti-RABV antibodies into the 97 brain might prevent or delay RABV dissemination in an early stage of rabies infection. 
